摘要肿瘤治疗方法的长足进步使得幸存者慢性肾脏病（CKD）的治疗成为越来越重要的临床问题。日本肾脏病学会、日本临床肿瘤学会、日本医学肿瘤学会和日本肾脏病药物治疗学会共同制订的《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》中对肿瘤幸存者中CKD的流行病学、影响因素及治疗选择进行了全面的论述，从临床实践的角度强调了在肿瘤幸存者中管理CKD的复杂性，并提出了针对这一特殊人群的个性化治疗建议。本文对该指南的这一章节进行解读，以期为临床医师提供参考。

abstractsWith the rapid progress of cancer treatment, the treatment of chronic kidney disease (CKD) in cancer survivors has become more and more important in clinical practice. The Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022, in which the epidemiology, influencing factors, and treatment options of CKD in cancer survivors was comprehensively discussed. The above guideline emphasizes the complexity of managing CKD in cancer survivors from the perspective of clinical practice, and puts forward personalized treatment recommendations for this special population. This article interprets this chapter in the guideline in order to provide reference for clinicians.